Speaker illustration

Doctor Anna Planavila

University of Barcelona, Barcelona (Spain)

Group leader of the Molecular Cardiology Laboratory (University of Barcelona, IBUB). PhD thesis in 2005. Excellent Cum Laude. Extraordinary Doctorate Award 2006. At 2005 she started a post-doctoral stay at the Maastricht Cardiovascular Research Institute (CARIM),(The Nehterlands); competitive postdoctoral grant MEC / Fullbright (Ministry of Education and Science of Spain). After that, she obtained a competitive postdoctoral contract Sara Borrell, Carlos III Health Institute, MCINN for research at Faculty of Biology. University of Barcelona (2008). Ramon y Cajal researcher (2016). Associate Professor (2021) Line of research: "Identification of new cardiokines, proteins secreted by the heart with autocrine, paracrine and/or endocrine properties that may be important both for the treatment of heart disease and its possible use as biomarkers for the diagnosis of heart diseases"

FGF15/FGF19 is involved in the development of cardiac hypertrophy

Event: Frontiers in CardioVascular Biomedicine 2022

Topic: Cardiac Hypertrophy

Session: Poster Session 1


Involvement of the Fgf21 system in obesity-associated cardiomyopathy

Event: Frontiers in CardioVascular Biology 2016

Topic: Metabolism / Diabetes mellitus

Session: Obesity and cardiac microvascular function


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb